Business Description
Madrigal Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US5588681057
Total Employee Number:
915Description
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.34 | |||||
Equity-to-Asset | 0.44 | |||||
Debt-to-Equity | 0.64 | |||||
Debt-to-EBITDA | -1.24 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 9.18 | |||||
Beneish M-Score | 1.29 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 11.4 | |||||
3-Year EPS without NRI Growth Rate | 9.6 | |||||
3-Year FCF Growth Rate | 13.2 | |||||
3-Year Book Growth Rate | 34.3 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 47.09 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 61.56 | |||||
9-Day RSI | 60.75 | |||||
14-Day RSI | 57.96 | |||||
3-1 Month Momentum % | -8.78 | |||||
6-1 Month Momentum % | -12.73 | |||||
12-1 Month Momentum % | 62.94 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.5 | |||||
Quick Ratio | 3.16 | |||||
Cash Ratio | 2.4 | |||||
Days Inventory | 348.77 | |||||
Days Sales Outstanding | 37.11 | |||||
Days Payable | 218.26 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.1 | |||||
Shareholder Yield % | -1.36 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 93.07 | |||||
Operating Margin % | -27.68 | |||||
Net Margin % | -27.32 | |||||
EBITDA Margin % | -24.82 | |||||
FCF Margin % | -24.01 | |||||
OCF Margin % | -23.67 | |||||
ROE % | -48.68 | |||||
ROA % | -26.4 | |||||
ROIC % | -457.18 | |||||
3-Year ROIIC % | -9.69 | |||||
ROC (Joel Greenblatt) % | -1675.87 | |||||
ROCE % | -31.7 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 5020.25 | |||||
PS Ratio | 11.27 | |||||
PB Ratio | 22.5 | |||||
Price-to-Tangible-Book | 22.73 | |||||
EV-to-EBIT | -41.62 | |||||
EV-to-Forward-EBIT | 33.06 | |||||
EV-to-EBITDA | -41.84 | |||||
EV-to-Forward-EBITDA | 32.73 | |||||
EV-to-Revenue | 10.38 | |||||
EV-to-Forward-Revenue | 7.9 | |||||
EV-to-FCF | -43.25 | |||||
| Price-to-Net-Current-Asset-Value | 24.46 | |||||
| Price-to-Net-Cash | 94.63 | |||||
Earnings Yield (Greenblatt) % | -2.4 | |||||
FCF Yield % | -2.22 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MDGL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Madrigal Pharmaceuticals Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1,132.49 | ||
| EPS (TTM) ($) | -12.8 | ||
| Beta | 1.4052 | ||
| 3-Year Sharpe Ratio | 0.66 | ||
| 3-Year Sortino Ratio | 1.39 | ||
| Volatility % | 68.78 | ||
| 14-Day RSI | 57.96 | ||
| 14-Day ATR ($) | 21.402015 | ||
| 20-Day SMA ($) | 501.307 | ||
| 12-1 Month Momentum % | 62.94 | ||
| 52-Week Range ($) | 284.0228 - 615 | ||
| Shares Outstanding (Mil) | 23.06 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Madrigal Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Madrigal Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-04 08:00 | In 121 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 120 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 08:00 | In 30 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 29 days | ||
| General meeting for 2026 | 2026-06-17 08:00 | 501.19 (-0.82%) | ||
| 47th Annual Global Goldman Sachs Health Care Conference | 2026-06-10 11:20 | 476.89 (+0.50%) | ||
| First quarter earnings conference call for 2026 | 2026-05-06 08:00 | 502.47 (-3.04%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 502.47 (-3.04%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-03 14:30 | 435.62 (+1.25%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-19 08:00 | 491.49 (+0.98%) |
Show
Entries
Madrigal Pharmaceuticals Inc Frequently Asked Questions
What is Madrigal Pharmaceuticals Inc(MDGL)'s stock price today?
The current price of MDGL is $528.99. The 52 week high of MDGL is $615.00 and 52 week low is $284.02.
When is next earnings date of Madrigal Pharmaceuticals Inc(MDGL)?
The next earnings date of Madrigal Pharmaceuticals Inc(MDGL) is 2026-08-05 Est..
Does Madrigal Pharmaceuticals Inc(MDGL) pay dividends? If so, how much?
Madrigal Pharmaceuticals Inc(MDGL) does not pay dividend.
Guru Commentaries on NAS:MDGL
No articles.
Press Release
Articles on Madrigal Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers